| Recruiting | Weight Management in Obese Cancer Patients During Curative Active Treatment NCT07058207 | Institut d'Investigació Biomèdica de Bellvitge | N/A |
| Active Not Recruiting | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal a NCT04147494 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed A NCT03834961 | Children's Oncology Group | Phase 2 |
| Terminated | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY NCT04060849 | Fred Hutchinson Cancer Center | Phase 1 |
| Withdrawn | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Commun NCT03804255 | ECOG-ACRIN Cancer Research Group | — |
| Recruiting | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers NCT03775616 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Active Not Recruiting | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Co NCT02713269 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy NCT03098277 | University of Southern California | N/A |
| Recruiting | UWCCC Molecular Tumor Board Registry NCT03023202 | University of Wisconsin, Madison | — |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring NCT04054154 | M.D. Anderson Cancer Center | N/A |
| Completed | Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Rem NCT02540876 | University of Chicago | Phase 1 |
| Active Not Recruiting | Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer NCT02517034 | City of Hope Medical Center | N/A |
| Completed | Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neuroco NCT02360215 | NRG Oncology | Phase 3 |
| Terminated | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma NCT02414724 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorec NCT02188264 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction NCT01907802 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01749384 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors NCT01552356 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous Sy NCT01538095 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid T NCT01017640 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectabl NCT00740805 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia NCT00503854 | M.D. Anderson Cancer Center | — |
| Completed | Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors NCT00085553 | National Cancer Institute (NCI) | Phase 1 |